Show simple item record

dc.contributor.authorAmin, Alpesh
dc.contributor.authorKeshishian, A
dc.contributor.authorTrocio, Jeffrey
dc.contributor.authorDina, Oluwaseyi
dc.contributor.authorLe, Hannah
dc.contributor.authorRosenblatt, Lisa
dc.contributor.authorLiu, Xianchen
dc.contributor.authorMardekian, Jack
dc.contributor.authorZhang, Qisu
dc.contributor.authorBaşer, Onur
dc.contributor.authorLien Vo
dc.date.accessioned2019-02-28T13:04:26Z
dc.date.accessioned2019-02-28T11:08:18Z
dc.date.available2019-02-28T13:04:26Z
dc.date.available2019-02-28T11:08:18Z
dc.date.issued2017en_US
dc.identifier.citationAmin, A., Keshishian, A., Zhang, Q., Trocio, J., Dina, O., Liu, X., Mardekian, J., ... Baser, O. (2017). Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Current Medical Research and Opinion, 33, 9, 1595-1604.en_US
dc.identifier.issn0300-7995
dc.identifier.issn1473-4877
dc.identifier.urihttp://dx.doi.org/10.1080/03007995.2017.1345729
dc.identifier.urihttps://hdl.handle.net/20.500.11779/685
dc.descriptionOnur Başer (MEF Author)en_US
dc.description.abstractObjective: To compare the risk and cost of stroke/systemic embolism (SE) and major bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular atrial fibrillation (NVAF) patients. Methods: Patients (65 years) initiating warfarin or DOACs (apixaban, rivaroxaban, and dabigatran) were selected from the Medicare database from 1 January 2013 to 31 December 2014. Patients initiating each DOAC were matched 1:1 to warfarin patients using propensity score matching to balance demographics and clinical characteristics. Cox proportional hazards models were used to estimate the risks of stroke/SE and major bleeding of each DOAC vs. warfarin. Two-part models were used to compare the stroke/SE- and major-bleeding-related medical costs between matched cohorts. Results: Of the 186,132 eligible patients, 20,803 apixaban-warfarin pairs, 52,476 rivaroxaban-warfarin pairs, and 16,731 dabigatran-warfarin pairs were matched. Apixaban (hazard ratio [HR]=0.40; 95% confidence interval [CI] 0.31, 0.53) and rivaroxaban (HR=0.72; 95% CI 0.63, 0.83) were significantly associated with lower risk of stroke/SE compared to warfarin. Apixaban (HR=0.51; 95% CI 0.44, 0.58) and dabigatran (HR=0.79; 95% CI 0.69, 0.91) were significantly associated with lower risk of major bleeding; rivaroxaban (HR=1.17; 95% CI 1.10, 1.26) was significantly associated with higher risk of major bleeding compared to warfarin. Compared to warfarin, apixaban ($63 vs. $131) and rivaroxaban ($93 vs. $139) had significantly lower stroke/SE-related medical costs; apixaban ($292 vs. $529) and dabigatran ($369 vs. $450) had significantly lower major bleeding-related medical costs. Conclusions: Among the DOACs in the study, only apixaban is associated with a significantly lower risk of stroke/SE and major bleeding and lower related medical costs compared to warfarin.en_US
dc.language.isoengen_US
dc.relation.ispartofCurrent Medical Research And Opinionen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectWarfarinen_US
dc.subjectstrokeen_US
dc.subjectdirect oral anticoagulantsen_US
dc.subjectatrial fibrillationen_US
dc.titleRisk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States medicare populationen_US
dc.typearticleen_US
dc.departmentİİSBF, Psikoloji Bölümüen_US
dc.identifier.volume33en_US
dc.identifier.issue9en_US
dc.identifier.startpage1595en_US
dc.identifier.endpage1604en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.description.wosidWOS:000407959900007en_US
dc.description.scopusid2-s2.0-85023186280en_US
dc.contributor.institutionauthorBaşer, Onur
dc.description.pubmedid28635338en_US
dc.description.woscitationindexScience Citation Index Expandeden_US
dc.identifier.wosqualityQ2 - Q3en_US
dc.description.WoSDocumentTypeArticleen_US
dc.description.WoSInternationalCollaborationUluslararası işbirliği ile yapılan - EVETen_US
dc.description.WoSPublishedMonthTemmuzen_US
dc.description.WoSIndexDate2017en_US
dc.description.WoSYOKperiodYÖK - 2016-17en_US
dc.identifier.doi10.1080/03007995.2017.1345729en_US
dc.identifier.scopusqualityQ1en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record